Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

This study is ongoing, but not recruiting participants.

Study NCT00563836 Information provided by Fresenius Biotech GmbH

First Received: November 23, 2007 Last Updated: March 28, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	November 2008 (Final data collection date for primary outcome measure)